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Abstract 
Background: E‑cadherin is a major component of adherens junctions that regulates cell shape and maintains tissue 
integrity. A complete loss or any decrease in cell surface expression of E‑cadherin will interfere with the cell‑to‑cell 
junctions’ strength and leads to cell detachment and escape from the primary tumor site. In this prospective study, 
three functional single nucleotide polymorphisms (−347G/GA, rs5030625; −160C/A, rs16260; +54C/T, rs1801026), 
were found to modulate E‑cadherin expression.
Methods: 577 DNA samples from breast cancer (BC) cases were genotyped by polymerase chain reaction‑restriction 
fragment length polymorphism (PCR–RFLP).
Results: We detected no significant correlations between each polymorphism and the clinical parameters of the 
patients whereas the GACC haplotype was significantly associated with low SBR grading. Overall survival analysis 
showed that both −347G/G and +54C/C wild (wt) genotypes had a significantly worse effect compared to the other 
genotypes (non‑wt). Moreover, carrying simultaneously both the −347 and +54 wt genotypes confers a significantly 
higher risk of death. However, with metastatic recurrence, the death‑rate was null in patients carrying the non‑wt 
genotypes, and attained 37% in those carrying the wt genotype. A multivariate analysis showed that these two poly‑
morphisms are independent prognostic factors for overall survival in BC patients.
Conclusions: Our results support the fact that E‑cadherin genetic variants control disease severity and progression 
and could be a marker of disease outcome. These findings could be useful in selecting patients that should be moni‑
tored differently.
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Background
In 2012, one out of four cancer cases is a breast cancer 
(BC) case [1]. In North African countries BC is also the 
commonest cancer among women, and the incidence 
rates are widely lower than in European Mediterranean 
countries [2]. The incidence is probably underestimated 
in these developing countries because of the difficulties 
related to screening and diagnostic programs. How-
ever, considering death rates, BC is the second cause of 
cancer death in more developed regions (198,000 deaths) 
and remains the most frequent in less developed regions 
(324,000 deaths). Yet, whatever socioeconomic status, 
it is well known that BC is a multifactorial disease, and 
that besides environment and lifestyle, the genetic back-
ground contributes to the increase of the risk of having 
breast cancer. While a huge amount of studies reported 
the involvement of genes, genetic loci or genetic poly-
morphisms in breast cancer susceptibility, studies of 
the genetic influence on disease progression and sever-
ity are less frequent [3]. Defining in gene-candidates, 
single nucleotide polymorphisms (SNPs) associated 
with increased severity or worsening progression of BC 
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of patients and as well as a better understanding of the 
mechanisms of cancer progression [4–6].
BC recurrence or metastasis represents the main cause 
of breast cancer-related deaths. It has been shown that 
epithelial-mesenchymal transition (EMT), a process by 
which epithelial cells acquire mesenchymal stem cell 
proprieties, plays a critical role in promoting metasta-
sis in carcinomas [7]. One of the initiating steps of EMT 
involves downregulation and relocation of the main 
epithelial cell adhesion protein, the epithelial-cadherin 
(E-cadherin) [8]. In normal epithelial tissues, E-cad-
herin is a major component of adherens junctions that 
regulates cell shape and maintains tissue integrity [9]. A 
complete loss of E-cadherin expression/function or any 
decrease in cell surface expression, caused by mutation 
of the CDH1 gene, or other mechanisms that decrease 
E-cadherin expression will interfere with the cell-to-cell 
junctions’ strength and leads, inter alia, to cell detach-
ment and escape from the primary tumor site. The CDH1 
gene (OMIM 192090) is located on chromosome 16q22, 
several single nucleotide polymorphisms (SNP) localized 
in non-coding sequences and affecting protein expres-
sion were described. The −347G/GA (rs5030625) and 
−160C/A (rs16260) SNPs within the promoter region 
are the most extensively studied CDH1-SNPs in disease 
association studies. Both the minor alleles were previ-
ously shown to reduce E-cadherin expression by affect-
ing the transcriptional efficiency of the CDH1 gene. The 
−347GA allele has weak transcriptional factor-binding 
strength and transcriptional activity compared with that 
of the G allele [10], while the −160A allele decreases the 
transcriptional efficiency compared with that of the C 
allele [11]. Additional regulatory polymorphisms outside 
of the promoter region that influence E-cadherin expres-
sion have also been reported. The +54C/T (rs1801026) 
is located at 141 bp upstream of the poly-A signal in the 
3′-UTR region. The study of Jacobs et al. showed that the 
occurrence of the T allele is related to a lower mRNA 
stability and also a reduced luciferase expression by a 
reporter gene constructs driven by a constitutive SV40-
promoter [12]. In regards to breast cancer, few investiga-
tions have been carried out on the association between 
CDH1 polymorphisms and cancer severity or progres-
sion. This is why in this prospective cohort study con-
ducted on 577 sporadic BC cases, three functional SNPs 
from of the E-cadherin gene (CDH1) were genotyped, 




The study was approved by the National Ethical Com-
mittee and a written informed consent was obtained 
from all enrolled individuals prior to their participation. 
Both patients and controls were collected between 2000 
and 2012 from the Farhat Hached University Hospital 
of Sousse (Tunisia). During blood sampling, all partici-
pants (patients and controls) were interviewed using a 
questionnaire to collect demographic characteristics, 
personal and family medical history, contraceptive meth-
ods, sexual and reproductive behavior information and 
lifestyle (smoking, alcohol consumption). In this study, 
unrelated participants without family history of breast 
cancer or any cancer were included. A total of 577 breast 
cancer patients were recruited from the Department of 
Cancerology and Radiotherapy (Farhat Hached Univer-
sity Hospital, Sousse, Tunisia). A detailed description 
of the clinico-pathological characteristics of this cohort 
is presented in Table 1. The patients had a mean age of 
48.7  ±  11  years (range 23–81). The median follow-up 
was 70  months (range 1–144  months). At the time of 
this study, 145 patients relapsed after treatment (local or 
distant recurrence). Among them, 31 patients died from 
breast carcinoma. To estimate linkage disequilibrium 
(LD), 300 Tunisian healthy blood donors without a per-
sonal history of cancer were recruited as control group 
from the Regional Center of Blood Transfusion (Farhat 
Hached University Hospital, Sousse, Tunisia).
Genomic DNA extraction and SNP genotyping analysis
Genomic DNA was extracted from peripheral blood leu-
kocytes by a “salting out” procedure [13]. Briefly, 10 ml of 
blood was mixed with Triton lysis buffer (0.32 M sucrose, 
1% Triton X-100, 5  mM MgCl2, 10  mM Tris–HCl, pH 
7.5). The pellet was incubated with proteinase K at 56 °C 
and subsequently salted out using a saturated NaCl solu-
tion. Precipitated proteins were removed by centrifuga-
tion. The DNA in supernatant fluid was precipitated with 
ethanol. Finally, the DNA pellet was conserved in Tris–
EDTA buffer. DNA concentration and quality were ana-
lyzed by thermo-scientific NanoDrop 2000™.
Genotype analysis of the CDH1 gene SNP −347 G/
GA (rs5030625), −160C/A (rs16260) and +54 C/T 
(rs1801026) polymorphisms were performed by polymer-
ase chain reaction-restriction fragment length polymor-
phism (PCR–RFLP) using previously described primers 
(Table  2) [14, 15]. Each PCR was performed under the 
standard conditions and the amplification was carried 
out in a final volume of 30  μl containing 25–100  ng of 
genomic DNA samples, 0.6  μM of each primer for the 
−160C/A and −347G/GA SNPs and 0.3  μM of each 
primer for the +54C/T SNP, 0.2 mM desoxy-nucleotide 
tryphosphate (dNTP), 1.5 mM MgCl2, 3 μl of 10 X PCR 
buffer and 0.5U of SuperTaq DNA polymerase (Amer-
sham, Paris, France). Reaction conditions used with 
thermal cycler (Biometra, Göttinger, Germany)were as 
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follows: For the promoter SNPs −160C/A and −347G/
GA the DNA was initially denatured for 5 min at 94  °C 
for 1 cycle, and incubated for 30 cycles: denaturing for 
30 s at 94  °C, annealing for 30 s at 61  °C and extending 
for 60  s at 72  °C. The +54C/T PCR reaction was car-
ried out in the same conditions described previously 
except for the annealing temperature, that was at 58  °C. 
A final extension of 7 min at 72 °C was performed at the 
end of each reaction. After amplification, PCR products 
were digested at 37 °C over night with 5U of the restric-
tion enzyme HphI for the −160C/A SNP, for 3 h with 3U 
of the restriction enzyme BanII for the −347G/GA and 
over night with 2U of the restriction enzyme PmlI for the 
+54C/T SNP. Digestion products were, then, separated 
on a 3% agarose gel stained with ethidium bromide and 
visualized with ultraviolet light.
Statistical analysis
To evaluate if our study population (patients and con-
trols) is in the Hardy–Weinberg equilibrium we used 
the Chi square test to compare between observed and 
expected genotype frequencies of CDH1 gene poly-
morphisms. The same test was used to evaluate any 
significant association between the three CDH1 poly-
morphisms and the clinicopathological characteristics of 
the disease. The differences were considered significant 
if the p value did not exceed 0.05. Odd ratios (ORs) and 
95% confidence intervals (CIs) were calculated by uncon-
ditional logistic regression. When expected values in 
contingency tables were under 5, Fisher’s exact test was 
used. The LD between SNPs pairs was quantified using 
the standardized linkage disequilibrium coefficient (D’) 
[16]. The haplotypes and their frequencies were esti-
mated using the Phase program [17].
Disease-free survival (DFS), metastasis-free survival 
(MFS), and overall survival (OS) were calculated using 
the Kaplan–Meier method for ten years and compared 
with the log-rank test. DFS was defined as the date of 
diagnosis until first recurrence, metastasis, death due 
to breast cancer or the last date of follow-up. MFS was 
defined as the date of diagnosis until first metastasis or 
last date of follow-up and OS was defined as the date of 
diagnosis until death due to breast cancer or last date of 
follow-up. Variables with a p-value less than 0.1 in the 
univariate Cox regression model were evaluated in a mul-
tivariate Cox regression model using the enter method. 
Because of the low number of the cases with metastasis 
at diagnosis (n = 10) we choose to exclude the metastasis 
parameter from the haplotypes and multivariate analysis. 
All statistics were carried out using Software Package for 
Social Sciences (SPSS) version 20.0 (SPSS, Chicago, IL, 
USA).
Results
CDH1 SNPs and their association with clinicopathological 
characteristics of breast cancer patients
All DNA samples were successfully genotyped for the 
three CHD1 SNPs (577 patients and 300 controls). For 
both patient and control groups all genotype distribu-
tions did not diverge significantly from Hardy–Weinberg 




 ≤40 133 (23.1)
 >40 444 (76.9)
Menopausal status
 Non menopausal 298 (51.6)
 Menopausal 279 (48.4)
Tumor size
 T1–T2 381 (66)
 T3–T4 167 (29)
 Unknown 29 (5)
Lymph node involvement
 Negative 230 (39.9)
 Positive 328 (56.8)
 Unknown 19 (3.3)
Metastasis
 Negative 362 (62.7)
 Positive 10 (1.7)
 Unknown 205 (35.5)
SBR grade
 SBR 1–2 329 (57)
 SBR 3 192 (33.3)
 Unknown 56 (9.7)
Histology
 Ductual 513 (88.9)
 Lobular 23 (4)
 Other 25 (4.3)
 Unknown 16 (2.8)
Estrogen receptor
 Negative 195 (33.8)
 Positive 255 (44.2)
 Unknown 127 (22)
Progesteron receptor
 Negative 240 (41.6)
 Positive 210 (36.4)
 Unknown 127 (22)
Her‑2 status
 Negative 75 (13)
 Positive 39 (6.8)
 Unknown 463 (80.2)
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equilibrium. Moreover, the minor allele frequencies 
(MAF) of these variants in the control population were 
close to those reported in Europeans (HapMap consor-
tium) (−347GA: 0.150; −160A: 0.322 and +54T: 0.206). 
Among the patients, the −347G/GA genotype frequen-
cies were 72.4% for GG, 24.8% for GGA and 2.8% for 
GAGA. For the −160C/A SNP, genotype frequencies 
were 45.9% for CC, 43.7% for CA and 10.4% for AA. The 
+54C/T genotype frequencies were 35.6% for CC, 47.1% 
for CT and 17.3% for TT.
We then investigated the association between CHD1 
SNP genotype distributions and clinicopathological char-
acteristics at diagnosis of patients with breast cancer. For 
each SNP genotype analysis, the patients were divided 
into homozygous wild-type carriers (wt) and non-carri-
ers (non-wt, heterozygous and homozygous mutant). The 
relationships between CHD1 SNP genotypes and clinico-
pathological characteristics are shown in Table 3. Over-
all, no statistically significant association was observed 
with any of the three SNPs and clinical characteristics, 
including age, menopausal status, tumor size, lymph 
node involvement, metastasis, SBR grading and histo-
logic type.
To analyze the association of the combined effects of 
the CDH1 SNPs and clinicopathological characteristics of 
patients with breast cancer, CDH1 haplotype frequencies 
and linkage disequilibrium coefficient were estimated. 
The haplotype frequencies among both patients and con-
trols are summarized in Table  4. Eight different haplo-
types were observed among both controls and patients 
with breast cancer. The −347G-160C  +  54C haplotype 
was the most frequent among both controls and patients. 
The −347G  −  160A  +  54T haplotype was significantly 
more frequently observed in patients than controls, 
and seemed to be a risk haplotype for BC occurrence 
(p  <  10−4, OR =  4.03). However, further larger popula-
tion-based case–control studies are necessary to validate 
these findings. The LD analysis results showed differ-
ent patterns between cases and controls. Both −347G/
GA and −160C/A loci, and −160C/A and +54C/T loci 
showed a stronger LD in controls compared to patients 
(D′  =  0.484 versus D′  =  0.279 and D′ =  0.473 versus 
D′ = 0.070). Moreover, the −347G/GA and +54C/T loci 
showed a higher LD in controls compared to patients (D′ 
=  0.083 versus D′  =  0.015). The relationships between 
CHD1 SNP haplotypes and clinicopathological character-
istics are shown in Table 5. The most frequent haplotype 
was used as a reference in the correlation analysis. The 
results showed that the −347GA − 160C + 54T haplo-
type was significantly more frequent among the younger 
women (age ≤ 40) (p = 0.01, OR = 0.37). However, the 
−347GA  −  160C  +  54C haplotype was significantly 
more frequent among patients aged more than 40 years 
(p  =  0.015, OR  =  3.74). The −347GA  −  160C  +  54C 
haplotype was also significantly more frequent among 
women with low SBR grading compared to high SBR 
grading (p = 0.049, OR = 0.44). There was no more sig-
nificant correlation of CDH1 haplotypes with clinical 
characteristics, including menopausal status, tumor size 
and lymph node involvement and histological type.
CDH1 SNPs and clinicopathological characteristics 
associated with survival in patients with breast cancer
When the relationship between the genotype distribu-
tion of the three SNPs in overall patients and the DFS and 
MFS was tested, no significant differences were observed 
(data not shown). However, the 10-years OS curve analy-
sis and log-rank testing showed that both the −347G/G 
and +54C/C wild homozygous genotypes had a signifi-
cantly worse effect on OS compared to the other geno-
types (survival rate: 90 versus 95% and 91 versus 99%, 
respectively) (Fig.  1). Moreover, when patients carrying 
simultaneously both the −347G/G and +54C/C geno-
types were grouped and compared to the non-carrier 
patients, the survival rate decreased to 87% for the wt-
carriers and increased to 100% for the non-wt carriers 
(Fig. 1).
Further analyses were conducted to investigate whether 
the −347G/GA and +54C/T SNPs were associated 
with overall survival, according to clinical character-
istics of the breast cancer patients (tumor size, lymph 
node involvement, SBR grading and metastasis occur-
rence after treatment). Significantly worse survival rates 
were observed in patients carrying the −347G/G wild 
homozygous genotype among patients with T3–T4 
tumor size (survival rates: 88 versus 100%), or positive 
Table 2 Primers and restriction enzymes used for polymorphism genotyping







BanII G: 263 + 116 + 68
GA: 332 + 116
HphI C: 181 + 177 + 89





PmlI C: 146 + 26
T: 172
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lymph node involvement (survival rates: 88 versus 99%), 
or high SBR grading (survival rates: 86 versus 100%) or 
metastasis occurrence after treatment (survival rates: 71 
versus 97%) (Fig. 2). No significant relationship was found 
with T1–T2 tumor size, negative lymph node involve-
ment, or low SBR grading and non-metastasis occurrence 
after treatment. Moreover, no significant relationship 
was found when the +54C/T SNP was analyzed accord-
ing to several patient subgroups. However, when we 
studied the combined effect of −347G/G and +54C/C 
genotypes on overall survival of the positive lymph node 
involvement (survival rates: 83 versus 100%), high SBR 
grading (survival rates: 80 versus 100%) and metastasis 
occurrence after treatment subgroups (survival rates: 63 
versus 100%), as noted previously, BC patients carrying 
simultaneously the wt genotypes had significantly worse 
survival rates (Fig. 2). Although the results were not sta-
tistically significant, when the combined effect was ana-
lyzed according to T3–T4 tumor size, they indicated 
that patients with −347G/G and +54C/C genotypes had 
the worst survival rate (survival rates: 86 versus 100%) 
(Fig. 2).
Univariate and multivariate analyses were used to eval-
uate whether the CDH1 SNPs and the clinicopathological 
characteristics were independent prognostic factors of 
breast cancer patients. The multivariate analysis showed 
that tumor size (p = 0.001, HR = 1.80) and lymph node 
involvement (p = 0.007, HR = 1.66) were independently 
associated with the DFS (Table  6). Moreover, it showed 
that lymph node involvement (p  =  0.018, HR  =  3.26), 
Table 3 Correlation between CDH1 SNPs and clinicopathological characteristics of breast cancer patients
CI confidence interval, OR odds ratio
a Fisher’s exact test
b Reference group
Characteristics −347 G/GA −160 C/A +54 C/T
GGb GGA + GAGA P OR (95% CI) CCb CA + AA P OR (95% CI) CCb CT + TT P OR (95% CI)
Age at diagnosis
 ≤40 96 37 61 72 48 85
 >40 322 122 0.93 0.98 (0.63–1.51) 204 240 0.98 0.99 (0.67–1.47) 157 287 0.87 1.03 (0.68–1.54)
Menopausal status
 Non menopausal 225 73 145 153 107 191
 Menopausal 193 86 0.08 1.37 (0.95–1.98) 120 159 0.17 1.25 (0.90–1.74) 98 181 0.84 1.03 (0.73–1.45)
Tumor size
 T1–T2 279 102 166 215 134 247
 T3–T4 119 48 0.63 1.1 (0.73–1.65) 81 86 0.28 0.82 (0.56–1.18) 61 106 0.76 0.94 (0.64–1.37)
Lymph node involvement
 Negative 167 63 116 114 73 157
 Positive 239 89 0.94 0.98 (0.67–1.44) 141 187 0.08 1.34 (0.96–1.80) 127 201 0.09 0.73 (0.51–1.05)
Metastasis
 Negative 264 98 166 196 121 241
 Positive 8 2 0.46a 0.67 (0.14–3.20) 3 7 0.25a 1.97 (0.50–7.70) 2 8 0.37a 2 (0.42–9.60)
SBR grade
 SBR 1–2 232 97 150 179 112 217
 SBR 3 148 44 0.10 0.71 (0.47–1.07) 91 101 0.69 0.93 (0.65–1.32) 74 118 0.30 0.82 (0.56–1.19)
Histology
 Ductual 376 137 240 273 183 330
 Lobular 18 5 0.59 0.76 (0.27–2.09) 11 12 0.92 0.95 (0.41–2.21) 6 17 0.35 1.57 (0.60–4.05)
Table 4 Haplotype frequencies of  CDH1 SNPs observed 
in breast cancer patients and controls
Haplotypes Frequencies P
−347G/GA −160C/A +54C/T Patients Controls
G C C 0.323 0.405
G C T 0.238 0.265 0.270
G A C 0.177 0.147 <10−4
G A T 0.109 0.032 <10−4
GA C C 0.068 0.101 0.380
GA C T 0.048 0.024 0.023
GA A C 0.022 0.021 0.660
GA A T 0.012 0.003 0.230
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SBR grade (p  =  0.048, HR  =  2.20), −347G/GA SNP 
(p  =  0.039, HR  =  0.12) and +54C/T SNP (p  =  0.022, 
HR = 0.40) were independent prognostic factors for OS 
in breast cancer patients (Table 6).
Discussion
Previous studies have shown that the development and 
the progression of epithelial cancers such as BC are 
related to the loss or the reduced expression of the main 
intercellular adhesion molecule of epithelial cells, the 
E-cadherin. The loss of cell-to-cell adhesion is an early 
event in metastatic colonization, leading to the detach-
ment of the cell from her tissue of origin to colonize 
other sites.
E-cadherin expression is under the control of func-
tional SNPs. As far as we know, reports were mainly case 
control-studies looking for risk of developing BC, and 
very few studies with controversial results were investi-
gated to identify the relationship between CDH1 genetic 
variants and clinicopathological features of the patients. 
In our study, none of the studied SNPs showed any sig-
nificant correlations with patients’ epidemiological or 
tumor or histological features. Shabnaz et al. also did not 
find any correlation between −160C/A polymorphisms 
with clinicopathological characteristics of BC patients 
[18]. However, Tipirisetti et  al. noted a positive correla-
tion between the −160A allele occurrences in patients 
with advanced stage [19]. In a Taiwanese study conducted 
on hepatocellular carcinoma patients, the occurrence of 
the −160A allele was significantly associated with more 
severe clinical stages [20]. Conversely, in a recent study 
of pancreatic cancer cases, the −160AA genotype was 
Table 5 Correlation between  CDH1 haplotype frequencies and  clinicopathological characteristics of  breast cancer 
patients
a Reference group
CI confidence interval, OR odds ratio
Characteristics GCCa GCT GAC GAT GACC GACT GAAC and GAAT
Age at diagnosis
 ≤40 0.358 0.213 0.194 0.084 0.027 0.094 0.030
 >40 0.312 0.248 0.173 0.117 0.081 0.032 0.036
 P 0.15 0.83 0.15 0.015 0.01 0.21
 OR (CI 95%) 1 1.38 (0.89–2.13) 1.06 (0.64–1.74) 1.54 (0.85–2.79) 3.74 (1.29–10.82) 0.37 (0.17–0.79) 1.37 (0.82–2.28)
Menopausal status
 Non menopausal 0.354 0.236 0.172 0.105 0.056 0.049 0.028
 Menopausal 0.291 0.245 0.182 0.114 0.081 0.043 0.044
 P 0.21 0.26 0.26 0.098 0.92 0.25
 OR (CI 95%) 1 1.26 (0.88–1.81) 1.29 (0.83–2.01) 1.29 (0.83–2.01) 1.69 (0.91–3.16) 1.04 (0.51–2.11) 1.73 (0.64–4.39)
Tumor size
 T1–T2 0.318 0.237 0.192 0.105 0.057 0.051 0.038
 T3–T4 0.326 0.242 0.149 0.124 0.085 0.038 0.035
 P 0.91 0.23 0.6 0.33 0.46 0.76
 OR (CI 95%) 1 0.98 (0.65–1.46) 0.73 (0.44–1.21) 1.13 (0.71–1.81) 1.41 (0.71–2.79) 0.74 (0.33–1.66) 0.86 (0.32–2.27)
Lymph node involvement
 Negative 0.320 0.284 0.162 0.084 0.053 0.047 0.050
 Positive 0.323 0.208 0.195 0.123 0.080 0.047 0.023
 P 0.19 0.34 0.24 0.29 0.91 0.19
 OR (CI 95%) 1 0.78 (0.54–1.13) 1.26 (0.78–2.04) 1.34 (0.82–2.17) 1.43 (0.74–2.77) 0.96 (0.47–1.95) 0.55 (0.22–1.81)
SBR grade
 SBR 1–2 0.314 0.225 0.167 0.131 0.086 0.047 0.030
 SBR 3 0.365 0.230 0.192 0.085 0.040 0.055 0.025
 P 0.46 0.96 0.053 0.049 0.97 0.84
 OR (CI 95%) 1 0.86 (0.57–1.29) 0.99 (0.61–1.61) 0.61 (0.37–1.00) 0.44 (0.19–0.99) 1.01 (0.50–2.05) 0.91 (0.34–2.42)
Histology
 Ductual 0.291 0.231 0.139 0.157 0.122 0.026 0.032
 Lobular 0.329 0.245 0.179 0.103 0.060 0.050 0.033
 P 0.74 0.83 0.2 0.11 0.52 0.72
 OR (CI 95%) 1.00 1.12 (0.57–2.22) 0.90 (0.35–2.34) 1.59 (0.78–3.23) 2.06 (0.86–4.94) 0.62 (0.14–2.67) 0.91 (0.54–1.52)
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found to be significantly associated with reduced risk 
with T stage, lymph node metastasis and pathologi-
cal stage [21]. In accordance with the previous results, 
a Japanese study of gastric cancer cases found that the 
−160CC genotype was significantly associated with deep 
invasion and lymph node metastasis [22]. Although pre-
vious studies were conducted mainly on epithelial cancer 
cases, a possible explanation of these contrasting results 
is the occurrence of one or more other SNPs, found in 
strong LD with the −160C/A in some ethnic groups (e.g. 
rs7200690, rs9929218). Further studies should be con-
ducted among different ethnic groups to help under-
standing these results.
To see the combined effects of the three functional 
SNPs the haplotype analysis was investigated. Weak 
LD values, generally associated with higher recom-
bination rates, were observed among patients [23]. 
Conversely, stronger LD values were observed among 
controls, suggesting a possible protective effect of the 
strong LD against BC. However, further investiga-
tions with a larger control sample size are needed to 
explain this result. To the best of our knowledge, this is 
the only study that explored the relationship between 
CDH1 haplotype frequencies and tumor severity. The 
−347GA −  160C +  54C haplotype may have a protec-
tive effect against high SBR grading. This haplotype has 
only one mutated allele at the −347 position, whilst 
having protective effect, however, the GA allelic analy-
sis did not show significant differences with the G allele 
when patients were compared according to SBR grading 
(p =  0.12, OR =  0.75). Although each SNP had a func-
tional impact on E-cadherin expression, the effects of 
their interactions and combinations are unknown, hence 
there is a need for further studies to describe the func-
tionality of haplotypes including these three SNPs.
Moreover, very few studies investigated the asso-
ciations of the CDH1 SNPs with patient survival. In a 
recent study conducted on a Chinese population, Jia 
et  al. showed that BC patients with low clinical tumor 
stages and carrying the minor allele genotype of an SNP 
(rs7200690) located in intron 2 in strong LD with the 
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Fig. 1 Overall survival curves of breast carcinoma patients according to the presence or absence of the wild type genotypes; a −347G/GA,  
b −160C/A, c +54C/T and d combined −347G/GA with +54C/T
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However, in a British population-based study no effect of 
the −160C/A SNP was seen on BC survival [25]. In the 
present study the −347G/GA and +54C/T SNPs, but 
not the −160C/A SNP, were shown to be associated with 
BC overall survival. When considering the whole patient 
group, both wild genotypes were shown to be associated 
with worse BC overall survival. Moreover, patients car-
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Fig. 2 Overall survival curves of different subgroups of breast carcinoma patients according to the presence or absence of the wild type genotypes 
of −347G/GA, +54C/T and combined −347G/GA with +54C/T
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+54C/C, had worse survival rates than those carrying 
one of each genotype. Interestingly, when considering 
more aggressive tumor subgroups (T3–T4, lymph node 
positive, high grade SBR and metastasis occurrence after 
treatment) we observed significantly worse survival rates 
with the −347G/G genotype and a decrease in survival 
when patients carry simultaneously the −347G/G and 
+54C/C genotypes. Herein we found that the CDH1 
−347G/G genotype confer risk of death in patients with 
more aggressive BC progression.
It is well known that in normal epithelial tissues, 
E-cadherin expression has suppressive effects on tumor 
progression, invasion and metastasis and thus any 
deregulation of E-cadherin expression could have criti-
cal pathological consequences. In a pathological context, 
E-cadherin expression could be modulated by several 
mechanisms, loss of heterozygosity, mutations of the 
CDH1 gene, epigenetic modulation, proteolytic process-
ing and also cadherin switching [9]. In BC, studies on 
E-cadherin tissue expression were conflicting. Most of 
them showed that reduced or loss of E-cadherin expres-
sion correlates with high histological grade, larger tumor 
size, nodal metastasis, development of distant metas-
tasis, and a reduced disease-free and overall survival 
[26–28]. However, in recent reports the involvement of 
E-cadherin in breast cancer severity and progression has 
increasingly been suggested [29, 30]. The ambiguous role 
of E-cadherin could be partially due to the existence of 
at least two different and functional forms of E-cadherin, 
a full-length membrane form and an extracellular pro-
teolytic soluble form (sE-cad). During the oncogenic 
process the first consequence of the E-cadherin prote-
olysis is the cell detachment and the release of a func-
tional sE-cad with cancer promoting functions. Inside 
the tumor microenvironment, sE-cad inhibits cell-to-
cell adhesion through an efficient competitive manner 
and by stimulating the activity of multiple matrix met-
alloproteinases (MMPs) [31]. Then, when sE-cad diffuse 
and spread into blood circulation, multiple oncogenic 
signaling pathways are activated [32, 33]. Recently, Liang 
et al., assessed the clinical significance of serum sE-cad 
levels in BC patients. They observed a significant cor-
relation of sE-cad levels with tumor stage, grade, lymph 
node metastasis and also survival [34]. Moreover, Hof-
mann et  al., found that serum sE-cad levels might be a 
marker predicting response to preoperative chemo-
therapy for patients with locally advanced breast cancer 
[35]. Functional SNPs modulate the expression of both 
Table 6 Clinicopathological characteristics associated with  disease-free survival and  overall survival in  patients 
with breast cancer
HR hazard ratio; ni not included in multivariate analysis
a ≤40 versus >40 years
b Non menopausal versus menopausal
c T1–T2 versus T3–T4
d Negative versus positive
e SBR 1–2 versus SBR 3
f Ductal invasive carcinoma versus Lobular invasive carcinoma
g Homozygous wild allele type versus heterozygous and mutates homozygous allele types
Characteristics Disease-free survival Overall survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Agea 0.74 0.51–1.08 0.121 ni 0.75 0.33–1.68 0.487 ni
Menopausal statusb 0.92 0.66–1.28 0.638 ni 0.87 0.42–1.76 0.702 ni
Tumor sizec 1.87 1.33–2.64 0.0003 1.80 1.27–2.56 0.001 1.44 0.69–3.02 0.326 ni
Lymph node involvementd 1.75 1.22–2.51 0.002 1.66 1.14–2.40 0.007 2.97 1.21–7.30 0.017 3.26 1.22–8.69 0.018
Metastasisd 3.03 1.47–6.22 0.003 ni 5.64 1.67–19.01 0.005 ni
SBR gradee 1.09 0.77–1.56 0.599 ni 2.29 1.08–4.84 0.030 2.20 1.00–4.81 0.048
Histologyf 1.62 0.82–3.20 0.157 ni 0.80 0.11–5.92 0.833 ni
Estrogen receptord 1.34 0.91–1.95 0.127 ni 0.73 0.33–1.60 0.435 ni
Progesteron receptord 1.16 0.80–1.67 0.419 ni 0.88 0.40–1.95 0.763 ni
Her‑2 statusd 1.03 0.44–2.40 0.938 ni 0.67 0.06–7.44 0.746 ni
CDH1 −347 G/GAg 0.92 0.63–1.35 0.694 ni 0.09 0.01–0.68 0.020 0.12 0.01–0.89 0.039
CDH1 −160 C/Ag 0.92 0.66–1.28 0.650 ni 1.27 0.62–2.63 0.505 ni
CDH1 +54 C/Tg 0.98 0.69–1.40 0.951 ni 0.52 0.26–1.06 0.075 0.40 0.18–0.87 0.022
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the membrane and the soluble E-cadherin forms in the 
same way. Since the two forms play opposite functions, 
the membrane form expressed in normal tissue acts as 
a tumor suppressor, while the soluble form associated 
with disease severity promotes tumor progression, this 
could explain why patients expected to have reduced 
E-cadherin expression have better survival whatever the 
severity of the disease.
Conclusions
This study provides novel information about the rela-
tionship between E-cadherin (CDH1) genetic variants 
and clinicopathological features and progression of 
BC. The main finding of this study is the association 
of CDH1 functional SNPs with overall survival in BC, 
particularly in patients with a more aggressive tumor at 
onset or with recurrent metastatic BC. Our results sup-
port the fact that the CDH1 SNPs control disease sever-
ity and progression and could be a marker of disease 
outcome. These findings could be useful in selecting 
patients who should be monitored differently. Addi-
tional investigations on functional evaluation of CDH1 
SNPs should be carried out to support our findings.
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